Know what a reportable test actually costs you. Veona consolidates consumables, reagents, QC control consumption, wastage, and overheads into one per-test cost framework, then compares expected against actual across tests, instruments, and time periods, so you find inefficiencies and price with confidence. It is built natively on Veona's stock weighted-average cost and general ledger, not a spreadsheet.
Most laboratories price tests on a guess, because the real cost of a reportable result is scattered across reagent invoices, consumable issues, the controls a QC run burns, the wastage nobody counts, and a share of overheads. Veona Cost Per Reportable Test pulls all of it into one framework, drawing component costs straight from stock at weighted-average cost and overheads from the general ledger, so there is one defensible cost per reportable test. It then compares the expected cost against what each test actually consumed, across tests, instruments, and time periods, surfacing where money leaks and where a price no longer covers the work. The result is costing you can stand behind in a tender, a payer negotiation, or a margin review, with no spreadsheet to reconcile.
A reportable test costs more than its reagent. CPRT consolidates the consumables and reagents it draws, the QC control consumption it shares, the wastage from expiry and repeats, and an allocated share of overheads into one per-test figure, so the number reflects the full cost of producing a result rather than the obvious part of it.
Component costs are drawn straight from stock at weighted-average cost, the same valuation the rest of Veona posts, and overheads from the general ledger, so the cost moves the moment a reagent price or an issue does. There is no parallel spreadsheet to maintain and no reconciliation, because CPRT reads the books the hospital already runs.
Set the expected cost of a test and CPRT compares it to what each run actually consumed, flagging the variance and what drove it, an over-issue, a higher reagent price, repeats, or wastage. The leaks are named rather than guessed at, so the lab fixes the few tests that move the number instead of trimming everywhere.
Slice cost per reportable test by instrument and by period to see which analyzer runs a test cheaply, where a reagent price rise has eroded margin, and how cost trends month over month. With the true cost in hand, set or defend a price in a tender or a payer negotiation knowing the margin is real, not assumed.
Reagents, consumables, QC, wastage, overheads.
Component costs at weighted-average cost.
Allocated straight from the general ledger.
Variance with the driver named.
See which analyzer runs a test cheaply.
Track cost trends month over month.
Set and defend prices on real margin.
Costing you can present and defend.
Native on the books you already run.
Reagents, QC, wastage, and overheads into one per-test cost.
Components from stock WAC, overheads from the general ledger.
Expected against actual, by test, instrument, and period.
Fix the driver and set a price on real margin.
Everything it takes to produce a result: the consumables and reagents the test draws, the QC controls it shares, the wastage from expiry and repeats, and an allocated share of overheads, consolidated into one defensible per-test figure.
Component costs are drawn from Veona Stock at weighted-average cost, the same valuation the rest of the platform posts, and overheads from the Veona Finance general ledger. There is no separate spreadsheet to maintain or reconcile.
You set an expected cost per test and CPRT compares it to what each run actually consumed, flagging the variance and its driver, whether an over-issue, a reagent price rise, repeats, or wastage, so you fix the few tests that move the number.
By comparing cost across tests, instruments, and time periods, you see where margin has eroded and which analyzer runs a test cheaply, so you can set or defend a price in a tender or a payer negotiation knowing the margin is real.
A walkthrough of the per-test cost framework, expected versus actual, built natively on stock WAC and the general ledger.